Biologic actions and therapeutic potential of the proglucagon-derived peptides (Q36575421)

15 August 2017

1 reference

title

Biologic actions and therapeutic potential of the proglucagon-derived peptides (English)

1 reference

15 August 2017

1

Daniel J Drucker

1 reference

15 August 2017

1 November 2005

1 reference

Nature Clinical Practice Endocrinology and Metabolism

15 August 2017

1 reference

15 August 2017

1

1 reference

15 August 2017

1

1 reference

15 August 2017

22-31

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpendmet0017

15 August 2017

0 references

cites work

Exon duplication and divergence in the human preproglucagon gene

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

International Union of Pharmacology. XXXV. The glucagon receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

The essential role of glucagon in the pathogenesis of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Diverse causes of hypoglycemia-associated autonomic failure in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the "switch-off" hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon and regulation of glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Amylin agonists: a novel approach in the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Role of gastrointestinal hormones in postprandial reduction of bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Glucagon-Like Peptide 2 Dose-Dependently Activates Intestinal Cell Survival and Proliferation in Neonatal Piglets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Short-term Administration of Glucagon-like Peptide-2. Effects on Bone Mineral Density and Markers of Bone Turnover in Short-Bowel Patients with No Colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

Oxyntomodulin suppresses appetite and reduces food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

7 January 2021

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

7 January 2021

Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

7 January 2021

Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

7 January 2021

Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

7 January 2021

Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

7 January 2021

Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

7 January 2021

Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0017

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0017

1 reference

PubMed ID

16929363

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

16929363